A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer

被引：0
|
作者：
Iwama, E. [1 ]
Sakai, K. [2 ]
Azuma, K. [3 ]
Nosaki, K. [4 ]
Harada, D. [5 ]
Hotta, K. [6 ]
Ohyanagi, F. [7 ]
Kurata, T. [8 ]
Akamatsu, H. [9 ]
Goto, K. [10 ]
Fukuhara, T. [11 ]
Nakanishi, Y. [1 ]
Nishio, K. [2 ]
Okamoto, I. [1 ]
机构：
[1] Kyushu Univ, Res Inst Dis Chest, Fukuoka 812, Japan
[2] Kinki Univ, Sch Med, Dept Genome Biol, Osakasayama, Japan
[3] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Fukuoka, Japan
[4] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan
[5] Shikoku Canc Ctr, Dept Thorac Oncol, Matsuyama, Ehime, Japan
[6] Okayama Univ Hosp, Resp Med, Okayama, Japan
[7] Canc Inst Hosp JFCR, Dept Thorac Med Oncol, Tokyo, Japan
[8] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan
[9] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[10] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
[11] Miyagi Canc Ctr, Dept Resp Med, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
484PD
引用
收藏
页码：148 / 149
页数：2
相关论文
共 50 条
  • [31] Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases
    Hochmair, Maximilian
    Holzer, Sophia
    Burghuber, Otto C.
    ANTI-CANCER DRUGS, 2016, 27 (09) : 914 - 915
  • [32] Efficacy of afatinib following osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
    Tamura, Tomohiro
    Okubo, Hatsumi
    Yamada, Yutaka
    Kikkawa, Yasuko
    Yamaguchi, Shozaburo
    Hashimoto, Ikuta
    Kaburagi, Takayuki
    ANNALS OF ONCOLOGY, 2021, 32 : S335 - S335
  • [33] ADVERSE EVENTS COSTS ASSOCIATED WITH ERLOTINIB OR AFATINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR MUTATION-POSITIVE TUMOURS
    Isla, D.
    De Castro, J.
    Juan Vidal, O.
    Grau, S.
    Orofino, J.
    Gordo, R.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    VALUE IN HEALTH, 2015, 18 (07) : A429 - A429
  • [34] Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
    Keiko Nakao
    Shinji Kobuchi
    Shuhei Marutani
    Ayano Iwazaki
    Akihiro Tamiya
    Shunichi Isa
    Kyoichi Okishio
    Masaki Kanazu
    Motohiro Tamiya
    Tomonori Hirashima
    Kimie Imai
    Toshiyuki Sakaeda
    Shinji Atagi
    Scientific Reports, 9
  • [35] Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
    Nakao, Keiko
    Kobuchi, Shinji
    Marutani, Shuhei
    Iwazaki, Ayano
    Tamiya, Akihiro
    Isa, Shunichi
    Okishio, Kyoichi
    Kanazu, Masaki
    Tamiya, Motohiro
    Hirashima, Tomonori
    Imai, Kimie
    Sakaeda, Toshiyuki
    Atagi, Shinji
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [36] Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer
    Ko, R.
    Oizumi, S.
    Mizugaki, H.
    Fujita, Y.
    Harada, T.
    Takashina, T.
    Igawa, S.
    Watanabe, K.
    Hotta, T.
    Minemura, H.
    Saeki, S.
    Yagishita, S.
    Hamada, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S568 - S568
  • [37] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Golembesky, Amanda
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2018, 14 (27) : 2861 - 2874
  • [38] Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
    Wang, Mengzhao
    Xu, Yan
    Zhao, Yanqiu
    Janne, Pasi A.
    Zhou, Jianying
    Wang, Yongsheng
    Fan, Yun
    Han, Zhigang
    Jin, Bo
    Ding, Cuimin
    Cheng, Ying
    Wu, Lin
    Liang, Li
    Hu, Ying
    Tang, Kejing
    Sun, Meili
    Song, Xia
    John, Tom
    Zhu, Xuehua
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer
    Yokota, Hayato
    Sato, Kazuhiro
    Sakamoto, Sho
    Okuda, Yuji
    Asano, Mariko
    Takeda, Masahide
    Nakayama, Katsutoshi
    Miura, Masatomo
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (04) : 652 - 659
  • [40] COMPARATIVE SAFETY PROFILE OF AFATINIB IN ASIAN AND NON-ASIAN PATIENTS WITH EGFR MUTATION-POSITIVE (EGFR M plus ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Sequist, Lecia V.
    Yang, James C.
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Schuler, Martin
    Mok, Tony
    Geater, Sarayut Lucien
    Massey, Daniel
    Wind, Sven
    O'Brien, Dennis
    Lorence, Robert
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1197 - S1197
12345